cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.11603712.v1
title: Supplementary Material for: Circulating Endocannabinoids and Mortality in Hemodialysis Patients

description: <b><i>Background:</i></b> Mortality in patients with end-stage renal disease (ESRD) on maintenance hemodialysis (MHD) remains exceptionally high. While traditional risk factors such as obesity are paradoxically associated with better survival, nontraditional risk factors including cachexia increase the likelihood of poor outcomes. There is accumulating evidence that the endocannabinoid (ECB) system plays a major role in energy preservation and storage, factors which can prevent the deleterious effects of cachexia. Hence, in this study, we evaluated the association of circulating ECB levels with mortality in MHD patients. <b><i>Methods:</i></b> Serum concentrations of anandamide (AEA) and 2-arachidonoyl-<i>sn</i>-glycerol (2-AG), major ECB ligands, were measured in MHD patients. Their correlation with various clinical/laboratory indices and association with 12-month all-cause mortality were examined. <b><i>Results:</i></b> Serum 2-AG levels positively correlated with body mass index, serum triglycerides and body anthropometric measures. Meanwhile, serum AEA levels correlated positively with serum interleukin-6, and negatively with serum very low-density lipoprotein levels. While increased serum 2-AG levels were associated with reduced risk of all-cause mortality (hazard ratio [HR] 0.52, 95% CI 0.28–0.98), there was no clear association between serum AEA levels and mortality (HR 0.91, 95% CI 0.48–1.72). <b><i>Conclusions:</i></b> In MHD patients, the circulating levels of ECB ligand, 2-AG, may play an important role in determining body mass and risk of mortality. These observations were unique to 2-AG as similar findings were not obtained with serum AEA. Future studies need to investigate the mechanisms responsible for these associations and examine the modulation of the ECB system as a potential target for therapy in ESRD.
DOI: 10.6084/m9.figshare.11603703
title: Supplementary Material for: Erklärung von Vilnius zu chronischen Atemwegserkrankungen: multisektorale Versorgungswege, die angeleitetes Selbstmanagement, mHealth und Luftverschmutzung bei der Versorgung chronischer Atemwegserkrankungen einschließen

description: <b>Hintergrund:</b> Mehr als eine Milliarde Menschen leiden an chronischen Atemwegserkrankungen wie Asthma, COPD, Rhinitis und Rhinosinusitis. Diese verursachen enorme Belastungen und gelten als schwerwiegende nicht übertragbare Erkrankungen. Viele Patienten sind noch unbehandelt und die Kosten der Untätigkeit sind nicht akzeptabel. Am 23. März 2018 fand in Vilnius eine Konferenz unter der Schirmherrschaft des Gesundheitsministeriums und verschiedener wissenschaftlicher Fachgesellschaften statt, auf der multisektorale Versorgungswege vorgeschlagen wurden, die angeleitetes Selbstmanagement, mHealth und Luftverschmutzung bei der Versorgung bestimmter chronischer Atemwegserkrankungen (Rhinitis, chronische Rhinosinusitis, Asthma und COPD) einschließen. Das Treffen schloss mit der Erklärung von Vilnius, die von den Teilnehmern des EU-Gipfels zu chronischen Atemwegserkrankungen unter der Federführung von Euforea entwickelt wurde. <b>Schlussfolgerung:</b> Die Erklärung von Vilnius ist ein wichtiger Schritt im Kampf gegen die weltweite Luftverschmutzung und ihre Auswirkungen für Patienten mit chronischen Atemwegserkrankungen und sie spielt im Hinblick auf die EU-Gesundheitsstrategie eine wichtige Rolle, da sie einen Zusatznutzen zu dem bereits vorhandenen Wissen über die öffentliche Gesundheit liefert.
DOI: 10.6084/m9.figshare.11603703.v2
title: Supplementary Material for: Erklärung von Vilnius zu chronischen Atemwegserkrankungen: multisektorale Versorgungswege, die angeleitetes Selbstmanagement, mHealth und Luftverschmutzung bei der Versorgung chronischer Atemwegserkrankungen einschließen

description: <b>Hintergrund:</b> Mehr als eine Milliarde Menschen leiden an chronischen Atemwegserkrankungen wie Asthma, COPD, Rhinitis und Rhinosinusitis. Diese verursachen enorme Belastungen und gelten als schwerwiegende nicht übertragbare Erkrankungen. Viele Patienten sind noch unbehandelt und die Kosten der Untätigkeit sind nicht akzeptabel. Am 23. März 2018 fand in Vilnius eine Konferenz unter der Schirmherrschaft des Gesundheitsministeriums und verschiedener wissenschaftlicher Fachgesellschaften statt, auf der multisektorale Versorgungswege vorgeschlagen wurden, die angeleitetes Selbstmanagement, mHealth und Luftverschmutzung bei der Versorgung bestimmter chronischer Atemwegserkrankungen (Rhinitis, chronische Rhinosinusitis, Asthma und COPD) einschließen. Das Treffen schloss mit der Erklärung von Vilnius, die von den Teilnehmern des EU-Gipfels zu chronischen Atemwegserkrankungen unter der Federführung von Euforea entwickelt wurde. <b>Schlussfolgerung:</b> Die Erklärung von Vilnius ist ein wichtiger Schritt im Kampf gegen die weltweite Luftverschmutzung und ihre Auswirkungen für Patienten mit chronischen Atemwegserkrankungen und sie spielt im Hinblick auf die EU-Gesundheitsstrategie eine wichtige Rolle, da sie einen Zusatznutzen zu dem bereits vorhandenen Wissen über die öffentliche Gesundheit liefert.
DOI: 10.6084/m9.figshare.11603703.v1
title: Supplementary Material for: Erklärung von Vilnius zu chronischen Atemwegserkrankungen: multisektorale Versorgungswege, die angeleitetes Selbstmanagement, mHealth und Luftverschmutzung bei der Versorgung chronischer Atemwegserkrankungen einschließen

description: <b>Hintergrund:</b> Mehr als eine Milliarde Menschen leiden an chronischen Atemwegserkrankungen wie Asthma, COPD, Rhinitis und Rhinosinusitis. Diese verursachen enorme Belastungen und gelten als schwerwiegende nicht übertragbare Erkrankungen. Viele Patienten sind noch unbehandelt und die Kosten der Untätigkeit sind nicht akzeptabel. Am 23. März 2018 fand in Vilnius eine Konferenz unter der Schirmherrschaft des Gesundheitsministeriums und verschiedener wissenschaftlicher Fachgesellschaften statt, auf der multisektorale Versorgungswege vorgeschlagen wurden, die angeleitetes Selbstmanagement, mHealth und Luftverschmutzung bei der Versorgung bestimmter chronischer Atemwegserkrankungen (Rhinitis, chronische Rhinosinusitis, Asthma und COPD) einschließen. Das Treffen schloss mit der Erklärung von Vilnius, die von den Teilnehmern des EU-Gipfels zu chronischen Atemwegserkrankungen unter der Federführung von Euforea entwickelt wurde. <b>Schlussfolgerung:</b> Die Erklärung von Vilnius ist ein wichtiger Schritt im Kampf gegen die weltweite Luftverschmutzung und ihre Auswirkungen für Patienten mit chronischen Atemwegserkrankungen und sie spielt im Hinblick auf die EU-Gesundheitsstrategie eine wichtige Rolle, da sie einen Zusatznutzen zu dem bereits vorhandenen Wissen über die öffentliche Gesundheit liefert.
DOI: 10.6084/m9.figshare.11603583
title: Supplementary Material for: Acupuncture Targeting SIRT1 in the Hypothalamic Arcuate Nucleus Can Improve Obesity in High-Fat-Diet-Induced Rats with Insulin Resistance via an Anorectic Effect

description: <b><i>Objective:</i></b> To investigate the anorexigenic and anti-obesity effectiveness of electroacupuncture (EA) on high-fat-diet-induced (HFDI) obese rats with insulin resistance (IR) and to reveal the possible mechanisms of EA affecting SIRT1 (silent mating type information regulation 2 homolog 1) in the central nervous system (CNS). <b><i>Methods:</i></b> We divided 60 rats into 6 groups. All interventions, including EA and intracerebroventricular administration, were performed after 8 weeks of model establishment. We tested obesity phenotypes like body weight (BW) gain; food intake; and IR levels including glucose infusion rate, intraperitoneal insulin tolerance test (IPITT), and intraperitoneal glucose tolerance test (IPGTT) during treatment. We detected protein expression and microscopic locations in hypothalamic SIRT1, the transcription factor FOXO1 (forkhead box protein O1), acetylated FOXO1 (Ac-FOXO1), pro-opiomelanocortin (POMC), and neuropeptide Y (NPY) via Western blotting and immunofluorescence, and monitored gene expression by real-time polymerase chain reaction. <b><i>Results:</i></b> Like the SIRT1 agonist, EA suppressed BW gain and IR levels in obese rats, but this was only partially blocked by the SIRT1 antagonist. EA could upregulate protein expression of hypothalamic SIRT1 and downregulate the acetylation level of FOXO1 in the hypothalamic arcuate nucleus (ARC), which decreased gene expression of NPY and increased that of POMC. The agonist targeted the hypothalamic <i>SIRT1</i> gene, unlike EA, which targeted posttranscriptional regulation. <b><i>Conclusion:</i></b> EA could improve obesity in HFDI rats with IR via its anorectic effect. This effect targeted posttranscriptional regulation of the <i>SIRT1</i> gene, which induced upregulation of ARC FOXO1 deacetylation and mediated the gene expression of POMC and NPY.
DOI: 10.6084/m9.figshare.11603583.v1
title: Supplementary Material for: Acupuncture Targeting SIRT1 in the Hypothalamic Arcuate Nucleus Can Improve Obesity in High-Fat-Diet-Induced Rats with Insulin Resistance via an Anorectic Effect

description: <b><i>Objective:</i></b> To investigate the anorexigenic and anti-obesity effectiveness of electroacupuncture (EA) on high-fat-diet-induced (HFDI) obese rats with insulin resistance (IR) and to reveal the possible mechanisms of EA affecting SIRT1 (silent mating type information regulation 2 homolog 1) in the central nervous system (CNS). <b><i>Methods:</i></b> We divided 60 rats into 6 groups. All interventions, including EA and intracerebroventricular administration, were performed after 8 weeks of model establishment. We tested obesity phenotypes like body weight (BW) gain; food intake; and IR levels including glucose infusion rate, intraperitoneal insulin tolerance test (IPITT), and intraperitoneal glucose tolerance test (IPGTT) during treatment. We detected protein expression and microscopic locations in hypothalamic SIRT1, the transcription factor FOXO1 (forkhead box protein O1), acetylated FOXO1 (Ac-FOXO1), pro-opiomelanocortin (POMC), and neuropeptide Y (NPY) via Western blotting and immunofluorescence, and monitored gene expression by real-time polymerase chain reaction. <b><i>Results:</i></b> Like the SIRT1 agonist, EA suppressed BW gain and IR levels in obese rats, but this was only partially blocked by the SIRT1 antagonist. EA could upregulate protein expression of hypothalamic SIRT1 and downregulate the acetylation level of FOXO1 in the hypothalamic arcuate nucleus (ARC), which decreased gene expression of NPY and increased that of POMC. The agonist targeted the hypothalamic <i>SIRT1</i> gene, unlike EA, which targeted posttranscriptional regulation. <b><i>Conclusion:</i></b> EA could improve obesity in HFDI rats with IR via its anorectic effect. This effect targeted posttranscriptional regulation of the <i>SIRT1</i> gene, which induced upregulation of ARC FOXO1 deacetylation and mediated the gene expression of POMC and NPY.
DOI: 10.6084/m9.figshare.11603574
title: Supplementary Material for: Lymph Node Ratio Can Better Predict Prognosis than Absolute Number of Positive Lymph Nodes in Operable Cervical Carcinoma

description: <b><i>Background:</i></b> Nodal status is the most important prognostic factor in cervical cancer. However, further risk stratification in node positive cervical cancer patients is warranted for optimal therapeutic decisions. <b><i>Material and Methods:</i></b> Nodal positive patients (<i>n</i> = 86) were retrospectively stratified into two groups according to either number of positive nodes (&gt;3 vs. 1–3) or lymph node ratio (LNR) (≥10 vs. &lt;10% and &gt;6.6 vs. ≤6.6%). Univariable log-rank tests and both univariable and adjusted multivariable Cox regression models were used to evaluate the association between number of positive nodes or LNR and disease-free survival (DFS) and overall survival (OS). <b><i>Results:</i></b> LNR was significantly associated with worse DFS in adjusted multivariable analysis, both when categorized as ≥10 versus &lt;10% (HR 2.25, 95% CI 1.06–4.76, <i>p</i> = 0.034) and when categorized as &gt;6.6 versus ≤6.6% (HR 2.79, 95% CI 1.23–6.37, <i>p</i> = 0.015). However, we found no significant association between number of positive nodes or LNR and OS. <b><i>Discussion:</i></b>In operable node-positive cervical cancer, both number of positive lymph nodes and LNR can be used for further risk stratification with regard to DFS but not OS.
DOI: 10.6084/m9.figshare.11603574.v1
title: Supplementary Material for: Lymph Node Ratio Can Better Predict Prognosis than Absolute Number of Positive Lymph Nodes in Operable Cervical Carcinoma

description: <b><i>Background:</i></b> Nodal status is the most important prognostic factor in cervical cancer. However, further risk stratification in node positive cervical cancer patients is warranted for optimal therapeutic decisions. <b><i>Material and Methods:</i></b> Nodal positive patients (<i>n</i> = 86) were retrospectively stratified into two groups according to either number of positive nodes (&gt;3 vs. 1–3) or lymph node ratio (LNR) (≥10 vs. &lt;10% and &gt;6.6 vs. ≤6.6%). Univariable log-rank tests and both univariable and adjusted multivariable Cox regression models were used to evaluate the association between number of positive nodes or LNR and disease-free survival (DFS) and overall survival (OS). <b><i>Results:</i></b> LNR was significantly associated with worse DFS in adjusted multivariable analysis, both when categorized as ≥10 versus &lt;10% (HR 2.25, 95% CI 1.06–4.76, <i>p</i> = 0.034) and when categorized as &gt;6.6 versus ≤6.6% (HR 2.79, 95% CI 1.23–6.37, <i>p</i> = 0.015). However, we found no significant association between number of positive nodes or LNR and OS. <b><i>Discussion:</i></b>In operable node-positive cervical cancer, both number of positive lymph nodes and LNR can be used for further risk stratification with regard to DFS but not OS.
DOI: 10.6084/m9.figshare.11603541
title: Supplementary Material for: Clinically Significant Visual Deficits after Laser Interstitial Thermal Therapy for Mesiotemporal Epilepsy

description: <b><i>Background:</i></b> Laser interstitial thermal therapy (LITT) has recently gained popularity as a minimally invasive surgical option for the treatment of mesiotemporal epilepsy (mTLE). Similar to traditional open procedures for epilepsy, the most frequent neurological complications of LITT are visual deficits; however, a critical analysis of these injuries is lacking. <b><i>Objectives:</i></b> To evaluate the visual deficits that occur after LITT for mTLE and their etiology. <b><i>Method:</i></b> We surveyed five academic epilepsy centers that regularly perform LITT for cases of self-reported postoperative visual deficits. For these patients all pre-, intra- and postoperative MRIs were co-registered with an anatomic atlas derived from 7T MRI data. This was used to estimate thermal injury to early visual pathways and measure imaging variables relevant to the LITT procedure. Using logistic regression, we then compared 14 variables derived from demographics, mesiotemporal anatomy, and the surgical procedure for the patients with visual deficits to a normal cohort comprised of the first 30 patients to undergo this procedure at a single institution. <b><i>Results:</i></b> Of 90 patients that underwent LITT for mTLE, 6 (6.7%) reported a postoperative visual deficit. These included 2 homonymous hemianopsias (HHs), 2 quadrantanopsias, and 2 cranial nerve (CN) IV palsies. These deficits localized to the posterior aspect of the ablation, corresponding to the hippocampal body and tail, and tended to have greater laser energy delivered in that region than the normal cohort. The patients with HH had insult localized to the lateral geniculate nucleus, which was ­associated with young age and low choroidal fissure CSF volume. Quadrantanopsia, likely from injury to the optic radiation in Meyer’s loop, was correlated with a lateral trajectory and excessive energy delivered at the tail end of the ablation. Patients with CN IV injury had extension of contrast to the tentorial edge associated with a mesial laser trajectory. <b><i>Conclusions:</i></b> LITT for epilepsy may be complicated by various classes of visual deficit, each with distinct etiology and clinical significance. It is our hope that by better understanding these injuries and their mechanisms we can eventually reduce their occurrence by identifying at-risk patients and trajectories and appropriately tailoring the ablation procedure.
DOI: 10.6084/m9.figshare.11603547.v1
title: Fagaceae collection

description: This fileset includes matrices and inferences relating to inferences and discussions about phylogenetic relationships in extant and extinct Fagaceae. See readme.txt in each archive for content and labelling conventions.<br><br><i><b>Version 1</b></i>Data, inferences, and exemplary artwork relevant for testing believes expressed in <br>Wilf P, Nixon KC, Gandolfo MA, Cúneo RA (2019). Eocene Fagaceae from Patagonia and Gondwanan legacy in Asian rainforests. <i>Science </i><b>364, </b>972based on a "phylogenetic analysis" of seven morphological traits.<i>Ockham's Razor applied but not used: can we do DNA-scaffolding with seven characters?</i><i>Why we want to map trait evolution on networks, pt. 1 – Introduction; pt. 2 – Topological ambiguity.</i><i></i><br><br>
DOI: 10.6084/m9.figshare.11603484
title: Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer

description: <b>Background:</b> Fluoropyrimidines are mainstay chemotherapeutics in the treatment of gastrointestinal cancers and are also used to treat breast cancer and head and neck cancers. However, 5-flourouracil (5-FU) and capecitabine may induce cardiotoxicity that mostly presents as acute coronary syndromes. We compared the incidence of cardiotoxicity induced by 5-FU and capecitabine in patients with colorectal cancer and sought to identify risk markers for cardiotoxicity. <b>Methods:</b> We reviewed all consecutive patients with colorectal cancer who received 5-FU or capecitabine at one institution in the neoadjuvant (2007–2016), adjuvant (2000–2016) or metastatic setting (2007–2016). <b>Results:</b> Totally, 995 patients received 5-FU and 1241 received capecitabine. The incidence of cardiotoxicity induced by 5-FU was 5.2% [95% confidence interval (CI): 3.8–6.6%] and 4.1% (95% CI: 3.0–5.2%) induced by capecitabine (<i>p</i> = .21). The most common events were angina without ischemia (5-FU: 1.6%, capecitabine: 1.3%, <i>p</i> = .53), angina with ischemia on ECG (5-FU: 0.9%, capecitabine: 0.8%, <i>p</i> = .53), unspecified chest pain (5-FU: 0.9%, capecitabine: 0.6%, <i>p</i> = .34), ST-elevation myocardial infarction (5-FU: 0.5%; capecitabine: 0.4%, <i>p</i> = .76) and non-ST-elevation myocardial infarction (5-FU: 0.7%, capecitabine: 0.5%, <i>p</i> = .50). Cardiac arrest or sudden death occurred in 0.5 and 0.4%, respectively (<i>p</i> = 1). No risk markers for cardiotoxicity induced by 5-FU were identified. In the capecitabine group, ischemic heart disease was a risk marker (odds ratio: 2.9, 95% CI: 1.2–7.0, <i>p</i> = .016). <b>Conclusions:</b> Five percent of patients treated with 5-FU developed cardiotoxicity and 4% treated with capecitabine. Ischemic heart disease was a risk marker for cardiotoxicity induced by capecitabine.
DOI: 10.6084/m9.figshare.11603478
title: Regulatory regions with modern human changes

description: Supplementary Tables 1 and 2 report all enhancers and promoters, active during the early stages of cortical development (5 to 20 PCW), harbouring modern human single-nucleotide changes (and depleted of archaic changes).<br>
DOI: 10.6084/m9.figshare.11603484.v1
title: Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer

description: <b>Background:</b> Fluoropyrimidines are mainstay chemotherapeutics in the treatment of gastrointestinal cancers and are also used to treat breast cancer and head and neck cancers. However, 5-flourouracil (5-FU) and capecitabine may induce cardiotoxicity that mostly presents as acute coronary syndromes. We compared the incidence of cardiotoxicity induced by 5-FU and capecitabine in patients with colorectal cancer and sought to identify risk markers for cardiotoxicity. <b>Methods:</b> We reviewed all consecutive patients with colorectal cancer who received 5-FU or capecitabine at one institution in the neoadjuvant (2007–2016), adjuvant (2000–2016) or metastatic setting (2007–2016). <b>Results:</b> Totally, 995 patients received 5-FU and 1241 received capecitabine. The incidence of cardiotoxicity induced by 5-FU was 5.2% [95% confidence interval (CI): 3.8–6.6%] and 4.1% (95% CI: 3.0–5.2%) induced by capecitabine (<i>p</i> = .21). The most common events were angina without ischemia (5-FU: 1.6%, capecitabine: 1.3%, <i>p</i> = .53), angina with ischemia on ECG (5-FU: 0.9%, capecitabine: 0.8%, <i>p</i> = .53), unspecified chest pain (5-FU: 0.9%, capecitabine: 0.6%, <i>p</i> = .34), ST-elevation myocardial infarction (5-FU: 0.5%; capecitabine: 0.4%, <i>p</i> = .76) and non-ST-elevation myocardial infarction (5-FU: 0.7%, capecitabine: 0.5%, <i>p</i> = .50). Cardiac arrest or sudden death occurred in 0.5 and 0.4%, respectively (<i>p</i> = 1). No risk markers for cardiotoxicity induced by 5-FU were identified. In the capecitabine group, ischemic heart disease was a risk marker (odds ratio: 2.9, 95% CI: 1.2–7.0, <i>p</i> = .016). <b>Conclusions:</b> Five percent of patients treated with 5-FU developed cardiotoxicity and 4% treated with capecitabine. Ischemic heart disease was a risk marker for cardiotoxicity induced by capecitabine.
DOI: 10.6084/m9.figshare.11603478.v1
title: Regulatory regions with modern human changes

description: Supplementary Tables 1 and 2 report all enhancers and promoters, active during the early stages of cortical development (5 to 20 PCW), harbouring modern human single-nucleotide changes (and depleted of archaic changes).<br>
DOI: 10.6084/m9.figshare.11603295
title: 2019 Clinical Trial Data Sharing Survey Results - Data

description: The full anonymised dataset from our recent survey into the attitudes towards clinical trial data sharing. The invitation to participate was distributed to clinical trialists funded by the Wellcome Trust, Bill and Melinda Gates Foundation, Cancer Research UK, and UK Medical Research Council.
DOI: 10.6084/m9.figshare.11603295.v1
title: 2019 Clinical Trial Data Sharing Survey Results - Data

description: The full anonymised dataset from our recent survey into the attitudes towards clinical trial data sharing. The invitation to participate was distributed to clinical trialists funded by the Wellcome Trust, Bill and Melinda Gates Foundation, Cancer Research UK, and UK Medical Research Council.
DOI: 10.6084/m9.figshare.11602932
title: Mykrobe data 2020-01-14

description: Mykrobe data 2020-01-14. Downloaded during the install process of mykrobe.